Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum

Last updated: March 23, 2026
Sponsor: Zuyderland Medisch Centrum
Overall Status: Completed

Phase

N/A

Condition

N/A

Treatment

Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))

Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)

Intercostal nerve cryoablation

Clinical Study ID

NCT05731973
Z2023005
  • Ages 12-24
  • All Genders

Study Summary

Primary objective of the current study is to determine the impact of intercostal nerve cryoablation on postoperative length of hospital stay compared to standard pain management of young pectus excavatum patients (12-24 years) treated with the minimal invasive Nuss procedure. The study is designed as a single center, prospective, unblinded, randomized clinical trial.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients undergoing the minimal invasive Nuss procedure for surgical repair ofpectus excavatum.

  • Young patients (12-24 years of age) according to the definition used by the WorldHealth Organization. This cut-off point is chosen to create a more homogenouspatient sample, as the thoracic cage is fully matured by the age of 24, in size anddensity, which will have an effect on postoperative pain.

Exclusion

Exclusion Criteria:

  • A chest wall deformity other than pectus excavatum;

  • Opioid use in the 3 months prior to surgery;

  • Pain syndrome (e.g., fibromyalgia) or neuropathic pain prior to surgical repair ofpectus excavatum;

  • Connective tissue disease (e.g., Marfan syndrome, Ehlers-Danlos syndrome);

  • Previous thoracic surgery or pectus excavatum repair;

  • Contraindication for intercostal nerve cryoablation or thoracic epidural analgesia (e.g., patient refusal, infection at the site of cannulation, uncontrolled systemicinfection, bleeding diathesis, increased intracranial pressure, mechanical spineobstruction);

  • Psychiatric disease currently receiving treatment;

  • Not mastering the Dutch language;

  • Participation in another clinical trial that may interfere with the current trial.

Study Design

Total Participants: 50
Treatment Group(s): 4
Primary Treatment: Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))
Phase:
Study Start date:
December 08, 2023
Estimated Completion Date:
October 22, 2025

Study Description

Rationale: The minimal invasive Nuss procedure is currently considered the treatment of choice for pectus excavatum. This procedure is usually associated with severe postoperative pain as great forces are employed on the thoracic cage to correct the sternal depression. Pain is the main limiting factor for early discharge. Epidural analgesia is currently considered gold standard for postoperative pain treatment. Alternative pain management strategies (e.g., patient-controlled analgesia and paravertebral nerve block) have also been described but fail in accomplishing adequate prolonged post-operative pain management. Alternatively, continuous use of opioids comes with side-effects like severe nausea, urinary retention and obstipation. Intercostal nerve cryoablation seems a promising novel technique for postoperative analgesia. Prior studies comparing intercostal cryoablation to other pain treatment modalities after pectus excavatum repair through the minimal invasive Nuss procedure report promising results, but pose significant limitations (e.g., small sample size, retrospective nature with non-matched patient groups or considerable confounders).

Objective: Primary objective of the current study is to determine the impact of intercostal nerve cryoablation on postoperative length of hospital stay compared to standard pain management of young pectus excavatum patients treated with the minimal invasive Nuss procedure.

Study design: The study protocol is designed for a single center, prospective, unblinded, randomized clinical trial.

Study population & intervention: Intercostal nerve cryoablation will be compared to thoracic epidural analgesia in young pectus excavatum patients (i.e., 12-24 years of age) treated with the minimal invasive Nuss procedure. Block randomization, including stratification based on age (12-16 years and 17-24 years) and sex, with an allocation ratio of 1:1 will be performed.

Main study parameters/endpoints: Postoperative length of hospital stay will be recorded as the primary endpoint. Secondary outcomes include: 1) pain intensity; 2) operative time; 3) opioid usage; 4) complications, including neuropathic pain; 5) creatine kinase activity; 6)intensive care unit admissions; 7) readmissions; 8) postoperative mobility; 9) health related quality of Life; 10) days to return to work/school; 11) number of postoperative outpatient visits and 12) hospital costs.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The risks for study participants are negligible as the cryoablation technique has already been effectively used in the Nuss procedure without any serious side effects. Also, participants will be monitored daily by nursing staff and surgeons while admitted to the hospital. Burden associated with participation in the current study consists of completion of several questionnaires preoperatively and postoperatively.

Connect with a study center

  • Zuyderland Medical Center

    Heerlen, Limburg 6419 PC
    Netherlands

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.